Article
Lumateperone for major depressive episodes in bipolar I or bipolar II disorder
- Author:
- Jonathan M. Meyer, MD
Among patients with bipolar I or II disorder (BD I or II), major depressive episodes represent the predominant mood state when not euthymic, and...
Article
Lumateperone for schizophrenia
- Author:
- Jonathan M. Meyer, MD
Lumateperone is a novel oral antipsychotic approved for the treatment of adult patients with schizophrenia.
Article
Risperidone extended-release injectable suspension
- Author:
- Jonathan M. Meyer, MD
RBP-7000 (Perseris) is the second long-acting injectable form of risperidone
approved in the United States.
Article
Aripiprazole lauroxil nanocrystal suspension
- Author:
- Jonathan M. Meyer, MD
New long-acting injectable formulation simplifies the initiation regimen.
Article
A concise guide to monoamine oxidase inhibitors: How to avoid drug interactions
- Author:
- Jonathan M. Meyer, MD
Use these strategies to maximize efficacy and minimize adverse effects when prescribing a monoamine oxidase inhibitor. Second of 2 parts.
Article
A concise guide to monoamine oxidase inhibitors
- Author:
- Jonathan M. Meyer, MD
A better understanding of the risks can lead to increased use of these highly effective agents. First of 2 parts.
Video
Dietary restrictions with MAOIs
- Author:
- Jonathan M. Meyer, MD
Jonathan M. Meyer, MD, discusses what to tell patients about diet and monoamine oxidase inhibitors.
Article
Deutetrabenazine for tardive dyskinesia
- Author:
- Jonathan M. Meyer, MD
Compared with first-generation antipsychotics, second-generation antipsychotics (SGAs) have a lower risk for extrapyramidal symptoms. Yet tardive...
Article
Valbenazine for tardive dyskinesia
- Author:
- Jonathan M. Meyer, MD
Despite improvements in the tolerability of antipsychotic medications, the development of tardive dyskinesia (TD) still is a significant area of...
Audio
Treating tardive dyskinesia
- Author:
- Jonathan M. Meyer, MD
Article
Pimavanserin for psychosis in patients with Parkinson’s disease
- Author:
- Jonathan M. Meyer, MD
Pimavanserin is a potent 5-HT2A inverse agonist and 5-HT2C inverse agonist, with 5-fold greater affinity for the 5-HT2A receptor.1...
Audio
Ketamine for treatment-resistant depression
- Author:
- Jonathan M. Meyer, MD
News
Is monitoring of plasma antipsychotic levels useful?
- Author:
- Jonathan M. Meyer, MD
The literature on plasma levels of antipsychotics documents the difficulties faced in establishing therapeutic ranges with the predictive power of...
News
Second of 2 parts: The mysteries of psychiatry maintenance of certification, further unraveled
- Author:
- Jonathan M. Meyer, MD
Stay on course with MOC by gaining close knowledge of its component requirements
News
A guide to the mysteries of maintenance of certification
- Author:
- Jonathan M. Meyer, MD
The MOC process is manageable, but you need to be conversant with its elements